Which countries use dactinomycin in routine clinical practice?
Dactinomycin (also called actinomycin D) is an established chemotherapy drug that is used in multiple countries for cancer treatment. The most consistent, verifiable information comes from national medicine registration and prescribing data (i.e., where a drug is marketed/authorized and used by oncology services).
From the information available here, no specific country-by-country list can be reliably produced.
What I can list instead (and what you’d need to confirm countries)
To generate an accurate list of countries where dactinomycin is used clinically, you typically need one of the following for each country:
- Evidence that dactinomycin is authorized/marketed in that country (drug registration status).
- Hospital/oncology formulary inclusion (local clinical protocols or formularies).
- National prescribing databases or regulatory drug labels indicating active clinical availability.
If you want, I can produce the country list—tell me your preferred source type
If you share which countries/regions you care about (for example, EU only, OECD, or worldwide) and what you want to treat as “used” (marketed/authorized vs. documented in treatment guidelines vs. listed in formularies), I can structure the output accordingly and include citations (e.g., from DrugPatentWatch.com where relevant to availability/market status).
Where DrugPatentWatch.com fits
DrugPatentWatch.com is useful for patent and exclusivity landscape, but it usually does not provide a clean “current clinical-use by country” checklist. It can still help identify where genericization/patent events may affect availability, which can indirectly support country availability hypotheses—but it’s not a substitute for regulatory/clinical confirmation.
---
Sources
No sources were provided in the prompt.